共 142 条
[1]
Jemal A(2011)Global cancer statistics CA Cancer J Clin 61 69-90
[2]
Bray F(2012)Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy Adv Urol 2012 921674-800
[3]
Centre MM(2009)Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents Mol Pharm 6 790-53
[4]
Ferlay J(2011)2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer Clin Cancer Res 17 7645-1093
[5]
Ward E(2011)123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy J Nucl Med 52 1087-823
[6]
Forman D(2012)[131I]MIP-1466, a small molecule prostate-specific membrane antigen (PSMA) inhibitor for targeted radiotherapy of prostate cancer (PCAa) J Nucl Med 53 170-1086
[7]
Kosuri S(2013)PSMA as a target for radiolabelled small molecules Eur J Nucl Med Mol Imaging 40 819-495
[8]
Akhtar NH(2012)[68Ga]Gallium-labelled PSMA-ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH Eur J Nucl Med Mol Imaging 39 1085-30
[9]
Smith M(2013)PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions Eur J Nucl Med Mol Imaging 40 486-20
[10]
Osborne JR(2013)PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer Eur J Nucl Med Mol Imaging 40 1629-551